莫德纳股票(MRNA)周一盘中大涨5.02%,引发市场高度关注。主要原因是,汇丰银行上调了莫德纳的评级至"买入"评级。
汇丰银行认为,莫德纳公司的管线产品如巨细胞病毒(CMV)疫苗,有望于2024年底公布3期临床数据,若获得成功,将使莫德纳成为这一尚未开发市场的先行者。汇丰银行预计莫德纳的主要管线产品能够帮助公司重拾增长动能。
同时,汇丰银行指出,如果莫德纳的现有主要管线产品能够顺利上市,并且RSV疫苗的发展压力得到缓解,那么莫德纳的估值就有可观的上升空间。总的来说,汇丰银行认为莫德纳公司目前的价值被市场低估。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.